Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Allergan should explore selling itself: Appaloosa's Tepper

Stock MarketsFeb 19, 2019 01:42PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. David Tepper, founder of Apploosa Management, speaks during the Sohn Investment Conference in New York

(Reuters) - Billionaire hedge fund manager David Tepper stepped up pressure on Allergan (NYSE:AGN) Plc, saying on Tuesday the drugmaker should consider selling itself if management is unable to turn around recent lagging performance.

Tepper's hedge fund Appaloosa LP wrote to Allergan's board, just hours after the Botox maker announced it added a former industry executive to its board but would split the roles of chairman and chief executive only when the person who now holds the positions is replaced.

"While we appreciate the input of Appaloosa as we do all of our shareholders, we strongly disagree that an immediate separation of the CEO and Chair positions is warranted," Allergan's board said in a statement.

Appaloosa has since last year pressed Allergan to separate the roles — currently held by Brent Saunders, who joined the company in 2014 — and recruit an outsider to oversee its board.

"If in fact (Allergan's) Board is unable or unwilling to hold management accountable for its shortcomings or find a suitable replacement, it is your fiduciary obligation to explore other options, including a merger or sale of the Company," Tepper said in the letter.

Splitting the chairman and CEO roles has become a favorite call for some investors who feel it would help companies be run better.

Earlier this month Appaloosa argued that by adding an independent chairman, Saunders might receive the help he needs to improve returns.

Allergan, however, said on Tuesday implementing Appaloosa's recommendations would be "highly disruptive" to the company's operations and impact Saunders' ability to continue to execute its current strategy.

Appaloosa, which oversees about $12 billion, cut its stake in Allergan by some 42 percent to nearly 1.2 million shares at the end of December, regulatory filings showed last week.

Allergan's shares have been lagging those of its industry peers — they have fallen 15 percent over the past year — since it dropped plans to sell some businesses, gave a disappointing revenue outlook for 2019 and as it faces rising competition for several important drugs.

The company earlier on Tuesday named Robert Hugin, a former CEO of U.S. drugmaker Celgene (NASDAQ:CELG), as a director, saying the appointment reflected its commitment to "active board refreshment."

Allergan should explore selling itself: Appaloosa's Tepper
 

Related Articles

Hope rally turns choppy as hot U.S. inflation looms
Hope rally turns choppy as hot U.S. inflation looms By Reuters - Dec 08, 2021 4

By Tom Westbrook SYDNEY (Reuters) - Stocks rose in choppy trade on Thursday as worries about the economic impact of the Omicron coronavirus variant ebbed but increasing caution...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email